+++ 821.676 Pressemeldungen +++ 33.979 Newsrooms +++ 6.000 Medien +++

BioTeSys selects Logos Technologies ALPHADAS eSource and pro-active EDC system to give clients real time access to study data

BioTeSys selects Logos Technologies ALPHADAS eSource and pro-active EDC system to give clients real time access to study data

(PresseBox) (Esslingen, ) Logos Technologies, the leading provider of EDC & CTMS solutions to the early phase clinical trial marketplace today announced that BioTeSys has chosen the market leading, early phase, e-source data capture system and site automation software suite, ALPHADAS which gives clinical research sites unsurpassed tools to accelerate and streamline their clinical trial operations and service.

”What is particularly exciting about our agreement with BioTeSys is that it is not only another client in Europe, but specifically our first Nutraceutical site. We see the exceptional client service that ALPHADAS can bring – real time data direct from the clinic floor, coupled with the industry leading expertise at BioTeSys as a compelling proposition for Nutraceutical sponsors the world over“, said Mark Cusack, VP of Business Development.

BioTeSys is a certificated partner (ISO 9001:2008) for development and realization of new concepts in the topics nutrition, Consumer Health Care and cosmetics.The examination and evaluation of the effects of biological active ingredients is the core competence that means the identification of functional characters of the ingredient or
of a mixture of ingredients as well as the examination of its effect and effectiveness. As entire service provider in the field of biological and chemical analysis the company offers a wide range of services, including the development of new proceedings and products on basis of customer orders. The service covers screening-procedures for recordal of bioactive potential of substances or substance mixtures by help of HPLC or photometry (accredited due to DIN/EN ISO EIC 17025), in vitro-test proceedings by utilization of single cell cultures, co-cultures and organic exemplars as well as planning and realization of clinical studies (according to ICH-GCP).The performed studies are focused on bioavailability-, effect- and efficacy-trials on a broad spectrum of physiologic background, substantiating questions in context of health claims for enriched foods, food supplements and medical foods (EbD).

The used measurement procedures, test systems and study documents permit a qualified characterization of substance- or product characters and are appropriate to support admission procedures. A network of additional analytic fellows, qualified specialist solicitors and evaluators complete the range of services.

ALPHADAS, is an e-Source, pro-active EDC automation system designed specifically for early phase clinical trials which has achieved great success. It is a market proven solution that offers a depth of functionality other systems cannot provide. In addition, through its modular and flexible structure ALPHADAS can be tailored to fit a client’s individual needs. It is a system that ‘fits all’, it can be installed progressively in modules, meeting both a clients’ immediate requirements but also their longer term goals, it is a solution that can be used by all companies, big and small.The dedicated team behind ALPHADAS are Experts in Early Phase EDC and provide an unrivalled level of service, experience and expertise to its clients. Logos Technologies continues to invest in ALPHADAS, even further increasing its performance and functionality making it the ‘System of Choice’ for early phase EDC.

LogosTechnologies Inc is a leading provider of world-class clinical trial solutions to pharmaceutical, biotechnology and clinical research organisations. ALPHADAS® is a proactive eSource clinical trials system that is mobile, schedule-driven, and provides real-time bedside or station based direct data capture. It meets the changing demands and time sensitive nature of early phase trials while integrating with clinical and laboratory operations. It accelerates data throughput, and enhances data integrity.

About BioTeSys GmbH

Die BioTeSys GmbH in Esslingen (www.biotesys.de) wurde 1999 gegründet und ist ein Spin-Off des Instituts für Biologische Chemie und Ernährungswissenschaften der Universität Hohenheim. BioTeSys ist Partner bei der Entwicklung und Umsetzung neuer Konzepte auf den Gebieten Kosmetik, Nahrungsmittel, und Consumer Health Care/OTC. Das Angebot umfasst Screening-Verfahren zur Erfassung des bioaktiven Potentials von Substanzen oder Substanzgemischen, in vitro-Testverfahren unter Verwendung von Einzelzellkulturen, Co-Kulturen und verschiedenen Organmodellen sowie klinische Studien. BioTeSys ist nach ISO 9001:2000 zertifiziert; die Abteilung Analytik mit den Schwerpunkten HPLC und Photometrie ist zusätzlich nach DIN EN ISO/IEC 17025:2005 akkreditiert. Alle verwendeten Messverfahren und Versuchsparameter sind auf physiologische Vorgaben hin entwickelt und optimiert. Die Ergebnisse und erhobenen Wirkkonzentrationen haben dadurch unmittelbare Aussagekraft für die Einschätzung biologischer Wirkungen.

Als kompletter Dienstleister auf dem Gebiet der biologischen und chemischen Analyse bietet das Unternehmen ein sehr weitreichendes Service-Angebot einschließlich der Entwicklung neuer Verfahren und Produkte im Kundenauftrag.

Diese Pressemitteilungen könnten Sie auch interessieren

News abonnieren

Mit dem Aboservice der PresseBox, erhalten Sie tagesaktuell und zu einer gewünschten Zeit, relevante Presseinformationen aus Themengebieten, die für Sie interessant sind. Für die Zusendung der gewünschten Pressemeldungen, geben Sie bitte Ihre E-Mail-Adresse ein.

Es ist ein Fehler aufgetreten!

Vielen Dank! Sie erhalten in Kürze eine Bestätigungsemail.